# US 2016/0250260 A1 · Small molecule cellular reprogramming to generate neuronal cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250260 A1
- Document ID: US20160250260A1
- Status: Published application
- Kind: A1
- Application number: 14/913,549
- Filed: 2014-08-26
- Published: 2016-09-01
- Earliest claimed: 2013-08-26
- Assignees: The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone
- Applicants: The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone
- Inventors: Changsheng Lin; Sheng Ding
- Web page: https://patentgrep.com/patent/US20160250260A1

## CPC

- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/688: both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0619: {Neurons}
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/395: Thyroid hormones
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/1307: from adult fibroblasts
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become neuronal cells.

## Claims

### Claim 1

A composition comprising the following agents: a GSK3 inhibitor, an ALK4/5/7 inhibitor, an HDAC inhibitor, and a p300 activator.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a PDE4 inhibitor, an Adenylyl cyclase agonist, a retinoic acid receptor γ agonist, a 5-HT3 antagonist, and a metabotropic glutamate (mGlu) receptor agonist.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The composition of claim 1, further comprising one or more of the following compounds: a ROCK inhibitor, a neuronal differentiation enhancer, an omega-3 fatty acid, an A3 adenosine receptor agonist or an L-type calcium channel blocker.

### Claim 5 (depends on 1)

The composition of claim 1, consisting essentially of the following compounds: CHIR99021 (GSK3 inhibitor), SB431542 (ALK4/5/7 inhibitor), MS275 (HDAC1 inhibitor), CTB (p300 activator), Rolipram (PDE4 inhibitor), Forskolin (Adenylyl cyclase agonist), CD1530 (RARγ receptor agonist), TDMB (Tropanyl-3,5-dimethylbenzoate, 5-HT3 antagonist), and ACPD (mGlu receptor agonist).

### Claim 6

A composition comprising the following compounds: a ROCK inhibitor, a neuronal differentiation enhancer, an omega-3 fatty acid, an A3 adenosine receptor agonist, and an L-type calcium channel blocker.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, further comprising a physiologically acceptable excipient or carrier.

### Claim 9 (depends on 1)

The composition of claim 1, wherein each of the agents is present in an amount sufficient to reprogram a cell into a neuronal cell type.

### Claim 10 (depends on 1)

The composition of claim 1, wherein each of the agents is present in an amount sufficient to induce a cell to express Tuj1, Tau, NeuN, MAP2, Synapsin, or any combination thereof.

### Claim 11 (depends on 1)

A method of generating a neuronal cell comprising contacting a selected cell with the composition of claim 1, to thereby generate a neuronal progenitor cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the selected cell contacted with the composition is a somatic cell, a differentiated cell, a population of cells, a heterogeneous mixture of cells, a non-neuronal cell, or a combination thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the selected cell is a newborn cord blood cell, or a newborn stem cell.

### Claim 14 (depends on 11)

The method of claim 11, wherein the selected cell is an allogenic or autologous cell.

### Claim 15 (depends on 11)

The method of claim 11, wherein the agent(s) or compound(s) is present in an amount sufficient to reprogram a cell into a neuronal cell type.

### Claim 16 (depends on 11)

The method of claim 11, wherein the agent(s) or compound(s) is present in an amount sufficient to induce a cell to express Tuj1, Tau, NeuN, MAP2, Synapsin, or any combination thereof.

### Claim 17 (depends on 11)

The method of claim 11, further comprising administering the neuronal progenitor cell to a subject.

### Claim 18 (depends on 1)

A method comprising administering the composition of claim 1, to a subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the composition contains one or more neuronal progenitor cells and/or one or more mature neuronal cells.

### Claim 20 (depends on 18)

The method of claim 18, wherein the subject suffers or is suspected of suffering from Amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, multiple sclerosis, Primary lateral sclerosis (PLS), Progressive bulbar palsy, Pseudobulbar palsy, Primary lateral sclerosis (PLS), Progressive muscular atrophy, Spinal muscular atrophy (SMA), including Type I (also called Werdnig-Hoffmann disease), Type II, Type III (Kugelberg-Welander disease), Fazio-Londe disease, Huntington's disease, Kennedy's disease also known as progressive spinobulbar muscular atrophy, hereditary spastic paraplegia (HSP), congenital SMA with arthrogryposis, Post-polio syndrome (PPS), traumatic spinal cord injury, progressive pseudobulbar palsy, progressive muscular atrophy, stroke, head trauma, spinal cord injury, or a combination thereof.

### Claim 21 (depends on 1)

A kit comprising the composition of claim 1, and instructions for using the composition.

### Claim 22 (depends on 21)

The kit of claim 21, further comprising components for in vitro cell culture of a selected cell.

### Claim 23 (depends on 21)

The kit of claim 21, further comprising a population of neuronal cells generated by contacting the cells with the composition.

### Claim 24 (depends on 21)

The kit of claim 21, further comprising a cell collection device, a diluent, a pharmaceutically acceptable carrier, a syringe, a catheter, a device for delivery of cells, a device for delivery of the composition to an animal, or any combination thereof.
